Venous thromboembolism in patients with essential thrombocythemia and polycythemia vera

Leukemia

Volumn 26, Issue 4, 2012, Pages 563-571

  Reikvam, H ^a,b   Tiu, R V ^c  

^a UNIVERSITY OF BERGEN   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^c TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

essential thrombocythemia; myeloproliferative neoplasms; novel therapeutics; polycythemia vera; thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA INTERFERON; ANAGRELIDE; ANTICOAGULANT AGENT; ANTIVITAMIN K; APIXABAN; BLOOD CLOTTING FACTOR 5; CLOPIDOGREL; HEPARIN; HISTONE DEACETYLASE INHIBITOR; HYDROXYUREA; ISOCITRATE DEHYDROGENASE; JANUS KINASE 2; JANUS KINASE 2 INHIBITOR; LENALIDOMIDE; LOW MOLECULAR WEIGHT HEPARIN; PARACETAMOL; RIVAROXABAN; THALIDOMIDE; VITAMIN K GROUP; WARFARIN;

ANTITHROMBIN III DEFICIENCY; ARTERY THROMBOSIS; BLEEDING; CARDIOVASCULAR RISK; CEREBRAL SINUS THROMBOSIS; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL (TOPIC); CONTROLLED CLINICAL TRIAL (TOPIC); DEEP VEIN THROMBOSIS; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG WITHDRAWAL; DYSLIPIDEMIA; EPIGENETICS; FEVER; FLU LIKE SYNDROME; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; GENE MUTATION; HEMATOPOIESIS; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; HYPERCHOLESTEROLEMIA; HYPERSPLENISM; HYPERTENSION; LOW DRUG DOSE; LUNG EMBOLISM; MOLECULAR GENETICS; MOOD DISORDER; MORBIDITY; MORTALITY; MULTIPLE MYELOMA; MYALGIA; PATHOPHYSIOLOGY; PHLEBOTOMY; POLYCYTHEMIA VERA; POSTOPERATIVE COMPLICATION; PREGNANCY; PRIMARY PREVENTION; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROTEIN C DEFICIENCY; PROTEIN S DEFICIENCY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; RISK FACTOR; SCREENING; SECONDARY PREVENTION; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; SPLENECTOMY; SPLENOMEGALY; THROMBOCYTE ACTIVATION; THROMBOCYTHEMIA; THROMBOPHILIA; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM; WEAKNESS;

HUMANS; JANUS KINASE 2; MUTATION; PHLEBOTOMY; POLYCYTHEMIA VERA; RISK FACTORS; THROMBOCYTHEMIA, ESSENTIAL; VENOUS THROMBOEMBOLISM;

EID: 84859631134     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2011.314     Document Type: Review

References (127)

1. WHO. World Health Organization Classification of Tumors of Haematopoietic and Lymphoid Tissues, 4th edn, International Agency for Cancer: Lyon, 2008.
2. Johansson P. Epidemiology of the myeloproliferative disorders polycythemia vera and essential thrombocythemia. Semin Thromb Hemost 2006; 32: 171-173.
3. Jensen MK, de Nully Brown P, Nielsen OJ, Hasselbalch HC. Incidence, clinical features and outcome of essential thrombocythaemia in a well defined geographical area. Eur J Haematol 2000; 65: 132-139. (Pubitemid 30615089)
4. Barbui T, Barosi G, Birgegard G, Cervantes F, Finazzi G, Griesshammer M et al. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol 2011; 29: 761-770.
5. Marchioli R, Finazzi G, Landolfi R, Kutti J, Gisslinger H, Patrono C et al. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol 2005; 23: 2224-2232. (Pubitemid 46218714)
6. Tefferi A, Vainchenker W. Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies. J Clin Oncol 2011; 29: 573-582.
7. Delhommeau F, Jeziorowska D, Marzac C, Casadevall N. Molecular aspects of myeloproliferative neoplasms. Int J Hematol 2010; 91: 165-173.
8. Levine RL. Mechanisms of mutations in myeloproliferative neoplasms. Best Pract Res Clin Haematol 2009; 22: 489-494.
9. Tefferi A. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia 2010; 24: 1128-1138.
10. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365: 1054-1061. (Pubitemid 40386783)
11. James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005; 434: 1144-1148. (Pubitemid 40663494)
12. Levine RL, Pardanani A, Tefferi A, Gilliland DG. Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nat Rev Cancer 2007; 7: 673-683. (Pubitemid 47327415)
13. Jamieson CH, Gotlib J, Durocher JA, Chao MP, Mariappan MR, Lay M et al. The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation. Proc Natl Acad Sci USA 2006; 103: 6224-6229.
14. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005; 7: 387-397. (Pubitemid 40544655)
15. Scott LM, Tong W, Levine RL, Scott MA, Beer PA, Stratton MR et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 2007; 356: 459-468. (Pubitemid 46193073)
16. Passamonti F, Elena C, Schnittger S, Skoda RC, Green AR, Girodon F et al. Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations. Blood 2011; 117: 2813-2816.
17. Delhommeau F, Dupont S, Della Valle V, James C, Trannoy S, Masse A et al. Mutation in TET2 in myeloid cancers. N Engl J Med 2009; 360: 2289-2301.
18. Tefferi A, Pardanani A, Lim KH, Abdel-Wahab O, Lasho TL, Patel J et al. TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia 2009; 23: 905-911.
19. Pardanani AD, Levine RL, Lasho T, Pikman Y, Mesa RA, Wadleigh M et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood 2006; 108: 3472-3476.
20. Vannucchi AM, Antonioli E, Guglielmelli P, Pancrazzi A, Guerini V, Barosi G et al. Characteristics and clinical correlates of MPL 515W > L/K mutation in essential thrombocythemia. Blood 2008; 112: 844-847.
21. Tefferi A, Lasho TL, Abdel-Wahab O, Guglielmelli P, Patel J, Caramazza D et al. IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic-or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis. Leukemia 2010; 24: 1302-1309.
22. Tiu RV, Gondek LP, O'Keefe CL, Elson P, Huh J, Mohamedali A et al. Prognostic impact of SNP array karyotyping in myelodysplastic syndromes and related myeloid malignancies. Blood 2011; 117: 4552-4560.
23. Bagot CN, Arya R. Virchow's triad: a question of attribution. Br J Haematol 2008; 143: 180-190.
24. Green D. Risk of future arterial cardiovascular events in patients with idiopathic venous thromboembolism. Hematology Am Soc Hematol Educ Program 2009, 259-266.
25. Prandoni P, Bilora F, Marchiori A, Bernardi E, Petrobelli F, Lensing AW et al. An association between atherosclerosis and venous thrombosis. N Engl J Med 2003; 348: 1435-1441. (Pubitemid 36407172)
26. Ginsburg AD. Platelet function in patients with high platelet counts. Ann Intern Med 1975; 82: 506-511.
27. Jensen MK, de Nully Brown P, Lund BV, Nielsen OJ, Hasselbalch HC. Increased platelet activation and abnormal membrane glycoprotein content and redistribution in myeloproliferative disorders. Br J Haematol 2000; 110: 116-124. (Pubitemid 30625599)
28. Falanga A, Marchetti M, Vignoli A, Balducci D, Barbui T. Leukocyte-platelet interaction in patients with essential thrombocythemia and polycythemia vera. Exp Hematol 2005; 33: 523-530. (Pubitemid 40592168)
29. Barbui T, Carobbio A, Rambaldi A, Finazzi G. Perspectives on thrombosis in essential thrombocythemia and polycythemia vera is leukocytosis a causative factor? Blood 2009; 114: 759-763.
30. Wautier MP, El Nemer W, Gane P, Rain JD, Cartron JP, Colin Y et al. Increased adhesion to endothelial cells of erythrocytes from patients with polycythemia vera is mediated by laminin alpha5 chain and Lu/BCAM. Blood 2007; 110: 894-901. (Pubitemid 47267426)
31. Pearson TC, Wetherley-Mein G. Vascular occlusive episodes and venous haematocrit in primary proliferative polycythaemia. Lancet 1978; 2: 1219-1222. (Pubitemid 9071903)
32. Duchemin J, Ugo V, Ianotto JC, Lecucq L, Mercier B, Abgrall JF. Increased circulating procoagulant activity and thrombin generation in patients with myeloproliferative neoplasms. Thromb Res 2010; 126: 238-242.
33. Barbui T, Carobbio A, Finazzi G, Vannucchi AM, Barosi G, Antonioli E et al. Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3. Haematologica 2011; 96: 315-318.
34. Rosti V, Bonetti E, Bergamaschi G, Campanelli R, Guglielmelli P, Maestri M et al. High frequency of endothelial colony forming cells marks a non-active myeloproliferative neoplasm with high risk of splanchnic vein thrombosis. PLoS One 2010; 5: e15277.
35. Sozer S, Fiel MI, Schiano T, Xu M, Mascarenhas J, Hoffman R. The presence of JAK2V617F mutation in the liver endothelial cells of patients with Budd-Chiari syndrome. Blood 2009; 113: 5246-5249.
36. Gruppo Italiano Studio Policitemia. Polycythemia vera: the natural history of 1213 patients followed for 20 years. Ann Intern Med 1995; 123: 656-664.
37. Radaelli F, Colombi M, Calori R, Zilioli VR, Bramanti S, Iurlo A et al. Analysis of risk factors predicting thrombotic and/or haemorrhagic complications in 306 patients with essential thrombocythemia. Hematol Oncol 2007; 25: 115-120. (Pubitemid 47507878)
38. Landolfi R, Di Gennaro L. Prevention of thrombosis in polycythemia vera and essential thrombocythemia. Haematologica 2008; 93: 331-335. (Pubitemid 351398632)
39. Besses C, Cervantes F, Pereira A, Florensa L, Sole F, Hernandez-Boluda JC et al. Major vascular complications in essential thrombocythemia: a study of the predictive factors in a series of 148 patients. Leukemia 1999; 13: 150-154. (Pubitemid 29092645)
40. Alvarez-Larran A, Cervantes F, Bellosillo B, Giralt M, Julia A, Hernandez-Boluda JC et al. Essential thrombocythemia in young individuals: frequency and risk factors for vascular events and evolution to myelofibrosis in 126 patients. Leukemia 2007; 21: 1218-1223. (Pubitemid 46831811)
41. Wolanskyj AP, Schwager SM, McClure RF, Larson DR, Tefferi A. Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors. Mayo Clin Proc 2006; 81: 159-166. (Pubitemid 43205767)
42. Passamonti F, Rumi E, Pungolino E, Malabarba L, Bertazzoni P, Valentini M et al. Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med 2004; 117: 755-761. (Pubitemid 39482529)
43. Ruggeri M, Gisslinger H, Tosetto A, Rintelen C, Mannhalter C, Pabinger I et al. Factor V Leiden mutation carriership and venous thromboembolism in polycythemia vera and essential thrombocythemia. Am J Hematol 2002; 71: 1-6. (Pubitemid 34988579)
44. Gisslinger H, Mullner M, Pabinger I, Heis-Vahidi-Fard N, Gisslinger B, Brichta A et al. Mutation of the prothrombin gene and thrombotic events in patients with polycythemia vera or essential thrombocythemia: a cohort study. Haematologica 2005; 90: 408-410. (Pubitemid 40388995)
45. Vannucchi AM, Antonioli E, Guglielmelli P, Longo G, Pancrazzi A, Ponziani V et al. Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden. Leukemia 2007; 21: 1952-1959. (Pubitemid 47299969)
46. Carobbio A, Finazzi G, Antonioli E, Guglielmelli P, Vannucchi AM, Dellacasa CM et al. JAK2V617F allele burden and thrombosis: a direct comparison in essential thrombocythemia and polycythemia vera. Exp Hematol 2009; 37: 1016-1021.
47. Antonioli E, Guglielmelli P, Poli G, Bogani C, Pancrazzi A, Longo G et al. Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia. Haematologica 2008; 93: 41-48. (Pubitemid 351156150)
48. Vannucchi AM, Antonioli E, Guglielmelli P, Rambaldi A, Barosi G, Marchioli R et al. Clinical profile of homozygous JAK2 617V > F mutation in patients with polycythemia vera or essential thrombocythemia. Blood 2007; 110: 840-846. (Pubitemid 47267419)
49. De Stefano V, Za T, Rossi E, Vannucchi AM, Ruggeri M, Elli E et al. Increased risk of recurrent thrombosis in patients with essential thrombocythemia carrying the homozygous JAK2 V617F mutation. Ann Hematol 2010; 89: 141-146.
50. Landolfi R, Di Gennaro L, Barbui T, De Stefano V, Finazzi G, Marfisi R et al. Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera. Blood 2007; 109: 2446-2452. (Pubitemid 46425887)
51. Glynn RJ, Danielson E, Fonseca FA, Genest J, Gotto Jr AM, Kastelein JJ et al. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med 2009; 360: 1851-1861.
52. Tefferi A, Lasho TL, Schwager SM, Strand JS, Elliott M, Mesa R et al. The clinical phenotype of wild-type, heterozygous, and homozygous JAK2V617F in polycythemia vera. Cancer 2006; 106: 631-635. (Pubitemid 43157627)
53. Vannucchi AM, Pieri L, Guglielmelli P. JAK2 allele burden in the myeloproliferative neoplasms: effects on phenotype, prognosis and change with treatment. Ther Adv Hematol 2011; 2: 21-32.
54. Passamonti F, Rumi E, Pietra D, Elena C, Boveri E, Arcaini L et al. A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. Leukemia 2010; 24: 1574-1579.
55. Buss DH, Stuart JJ, Lipscomb GE. The incidence of thrombotic and hemorrhagic disorders in association with extreme thrombocytosis: an analysis of 129 cases. Am J Hematol 1985; 20: 365-372. (Pubitemid 16222303)
56. Tefferi A, Gangat N, Wolanskyj AP. Management of extreme thrombocytosis in otherwise low-risk essential thrombocythemia; does number matter? Blood 2006; 108: 2493-2494. (Pubitemid 44497538)
57. Harrison CN, Campbell PJ, Buck G, Wheatley K, East CL, Bareford D et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med 2005; 353: 33-45. (Pubitemid 41007805)
58. Tefferi A, Elliott M. Thrombosis in myeloproliferative disorders: prevalence, prognostic factors, and the role of leukocytes and JAK2V617F. Semin Thromb Hemost 2007; 33: 313-320. (Pubitemid 46878103)
59. Campbell PJ, Scott LM, Buck G, Wheatley K, East CL, Marsden JT et al. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet 2005; 366: 1945-1953. (Pubitemid 41713984)
60. Za T, Fiorini A, Rossi E, Ciminello A, Chiusolo P, Leone G et al. Prevalence of the JAK2 V617F mutation in patients with unprovoked venous thromboembolism of common sites and without overt myeloproliferative neoplasms. Br J Haematol 2009; 144: 965-967.
61. Ugo V, Le Gal G, Lecucq L, Mottier D, Oger E. Prevalence of the JAK2 V617F mutation is low among unselected patients with a first episode of unprovoked venous thromboembolism. J Thromb Haemost 2008; 6: 203-205.
62. Remacha AF, Estivill C, Sarda MP, Mateo J, Souto JC, Canals C et al. The V617F mutation of JAK2 is very uncommon in patients with thrombosis. Haematologica 2007; 92: 285-286. (Pubitemid 46852446)
63. Pardanani A, Lasho TL, Hussein K, Schwager SM, Finke CM, Pruthi RK et al. JAK2V617F mutation screening as part of the hypercoagulable work-up in the absence of splanchnic venous thrombosis or overt myeloproliferative neoplasm: assessment of value in a series of 664 consecutive patients. Mayo Clin Proc 2008; 83: 457-459. (Pubitemid 351536475)
64. Colaizzo D, Amitrano L, Iannaccone L, Vergura P, Cappucci F, Grandone E et al. Gain-of-function gene mutations and venous thromboembolism: distinct roles in different clinical settings. J Med Genet 2007; 44: 412-416. (Pubitemid 46953726)
65. Rossi D, Cresta S, Destro T, Vendramin C, Bocchetta S, De Paoli L et al. JAK2V617F in idiopathic venous thromboembolism occurring in the absence of inherited or acquired thrombophilia. Br J Haematol 2007; 138: 813-814. (Pubitemid 47313208)
66. Regina S, Herault O, D'Alteroche L, Binet C, Gruel Y. JAK2 V617F is specifically associated with idiopathic splanchnic vein thrombosis. J Thromb Haemost 2007; 5: 859-861. (Pubitemid 46563588)
67. Zerjavic K, Zagradisnik B, Stangler Herodez S, Lokar L, Glaser Krasevac M, Kokalj Vokac N. Is the JAK2 V617F mutation a hallmark for different forms of thrombosis? Acta Haematol 2010; 124: 49-56.
68. Shetty S, Kulkarni B, Pai N, Mukundan P, Kasatkar P, Ghosh K. JAK2 mutations across a spectrum of venous thrombosis cases. Am J Clin Pathol 2010; 134: 82-85.
69. Kiladjian JJ, Cervantes F, Leebeek FW, Marzac C, Cassinat B, Chevret S et al. The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases. Blood 2008; 111: 4922-4929.
70. Kurosawa H, Okuya M, Matsushita T, Kubota T, Endoh K, Kuwashima S et al. JAK2V617F mutation-positive childhood essential thrombocythemia associated with cerebral venous sinus thrombosis. J Pediatr Hematol Oncol 2009; 31: 678-680.
71. Richard S, Perrin J, Lavandier K, Lacour JC, Ducrocq X. Cerebral venous thrombosis due to essential thrombocythemia and worsened by heparin-induced thrombocytopenia and thrombosis. Platelets 2011; 22: 157-159.
72. Lentini S, Barone M, Benedetto F, Spinelli F. Superior vena cava syndrome in a patient with polycythemia vera: diagnosis and treatment. Cardiol Res Pract 2010; 2010: 791648.
73. Yuan SM, Shinfeld A, Raanani E. Massive intraventricular thrombus in polycythemia vera. J Card Surg 2009; 24: 110-112.
74. Boissinot M, Lippert E, Girodon F, Dobo I, Fouassier M, Masliah C et al. Latent myeloproliferative disorder revealed by the JAK2-V617F mutation and endogenous megakaryocytic colonies in patients with splanchnic vein thrombosis. Blood 2006; 108: 3223-3224.
75. Colaizzo D, Amitrano L, Tiscia GL, Scenna G, Grandone E, Guardascione MA et al. The JAK2 V617F mutation frequently occurs in patients with portal and mesenteric venous thrombosis. J Thromb Haemost 2007; 5: 55-61. (Pubitemid 44921067)
76. De Stefano V, Fiorini A, Rossi E, Za T, Farina G, Chiusolo P et al. Incidence of the JAK2 V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disorders. J Thromb Haemost 2007; 5: 708-714. (Pubitemid 46563568)
77. McMahon C, Abu-Elmagd K, Bontempo FA, Kant JA, Swerdlow SH. JAK2 V617F mutation in patients with catastrophic intra-abdominal Thromboses. Am J Clin Pathol 2007; 127: 736-743.
78. Patel RK, Lea NC, Heneghan MA, Westwood NB, Milojkovic D, Thanigaikumar M et al. Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd-Chiari syndrome. Gastroenterology 2006; 130: 2031-2038. (Pubitemid 43816970)
79. Primignani M, Barosi G, Bergamaschi G, Gianelli U, Fabris F, Reati R et al. Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis. Hepatology 2006; 44: 1528-1534. (Pubitemid 44953658)
80. Smalberg JH, Darwish Murad S, Braakman E, Valk PJ, Janssen HL, Leebeek FW. Myeloproliferative disease in the pathogenesis and survival of Budd-Chiari syndrome. Haematologica 2006; 91: 1712-1713. (Pubitemid 46032973)
81. Tondeur S, Boutruche S, Biron-Andreani C, Schved JF. Prevalence of the JAK2 V617F mutation associated with splanchnic vein thrombosis. A 10-year retrospective study. Thromb Haemost 2009; 101: 787-789.
82. Xavier SG, Gadelha T, Pimenta G, Eugenio AM, Ribeiro DD, Gomes FM et al. JAK2V617F mutation in patients with splanchnic vein thrombosis. Dig Dis Sci 2010; 55: 1770-1777.
83. Gangat N, Wolanskyj AP, Tefferi A. Abdominal vein thrombosis in essential thrombocythemia: prevalence, clinical correlates, and prognostic implications. Eur J Haematol 2006; 77: 327-333. (Pubitemid 44337326)
84. De Stefano V, Za T, Rossi E, Vannucchi AM, Ruggeri M, Elli E et al. Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments. Haematologica 2008; 93: 372-380. (Pubitemid 351398638)
85. Lyman GH, Khorana AA, Falanga A, Clarke-Pearson D, Flowers C, Jahanzeb M et al. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 2007; 25: 5490-5505. (Pubitemid 350232226)
86. Warkentin TE. Think of HIT. Hematology Am Soc Hematol Educ Program 2006, 408-414.
87. Spectre G, Kalish Y, Schliamser L, Varon D. Heparin-induced thrombocytopenia in myeloproliferative disorders: a rare or underdiagnosed complication? Am J Hematol 2008; 83: 420-423. (Pubitemid 351614759)
88. Randi ML, Tezza F, Scapin M, Duner E, Scarparo P, Scandellari R et al. Heparin-induced thrombocytopenia in patients with Philadelphia-negative myeloproliferative disorders and unusual splanchnic or cerebral vein thrombosis. Acta Haematol 2010; 123: 140-145.
89. Tartaglia AP, Goldberg JD, Berk PD, Wasserman LR. Adverse effects of antiaggregating platelet therapy in the treatment of polycythemia vera. Semin Hematol 1986; 23: 172-176.
90. Gruppo Italiano Studio Policitemia (GISP). Low-dose aspirin in polycythaemia vera: a pilot study. Br J Haematol 1997; 97: 453-456.
91. Patrono C, Rocca B. Aspirin, 110 years later. J Thromb Haemost 2009; 7 (Suppl 1): 258-261.
92. Landolfi R, Marchioli R, Kutti J, Gisslinger H, Tognoni G, Patrono C et al. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med 2004; 350: 114-124. (Pubitemid 38056222)
93. Squizzato A, Romualdi E, Middeldorp S. Antiplatelet drugs for polycythaemia vera and essential thrombocythaemia. Cochrane Database Syst Rev 2008, CD006503.
94. Alvarez-Larran A, Cervantes F, Pereira A, Arellano-Rodrigo E, Perez-Andreu V, Hernandez-Boluda JC et al. Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia. Blood 2010; 116: 1205-1210; quiz 1387.
95. Paikin JS, Eikelboom JW, Cairns JA, Hirsh J. New antithrombotic agents-insights from clinical trials. Nat Rev Cardiol 2010; 7: 498-509.
96. Berk PD, Goldberg JD, Silverstein MN, Weinfeld A, Donovan PB, Ellis JT et al. Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy. N Engl J Med 1981; 304: 441-447. (Pubitemid 11178999)
97. Marchioli R, Finazzi G, Specchia G, Masciulli A, Mennitto MR, Barbui T. The CYTO-PV: A large-scale trial testing the intensity of cytoreductive therapy to prevent cardiovascular events in patients with polycythemia vera. Thrombosis 2011; 2011: 794240.
98. Cortelazzo S, Finazzi G, Ruggeri M, Vestri O, Galli M, Rodeghiero F et al. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med 1995; 332: 1132-1136.
99. Bjorkholm M, Derolf AR, Hultcrantz M, Kristinsson SY, Ekstrand C, Goldin LR et al. Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms. J Clin Oncol 2011; 29: 2410-2415.
100. Kiladjian JJ, Chomienne C, Fenaux P. Interferon-alpha therapy in bcr-abl-negative myeloproliferative neoplasms. Leukemia 2008; 22: 1990-1998.
101. Silver RT. Long-term effects of the treatment of polycythemia vera with recombinant interferon-alpha. Cancer 2006; 107: 451-458. (Pubitemid 44107203)
102. Quintas-Cardama A, Kantarjian H, Manshouri T, Luthra R, Estrov Z, Pierce S et al. Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J Clin Oncol 2009; 27: 5418-5424.
103. Kiladjian JJ, Cassinat B, Chevret S, Turlure P, Cambier N, Roussel M et al. Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood 2008; 112: 3065-3072.
104. Emadi A, Spivak JL. Anagrelide: 20 years later. Expert Rev Anticancer Ther 2009; 9: 37-50.
105. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344: 1031-1037. (Pubitemid 32267972)
106. Wang ZY, Chen Z. Acute promyelocytic leukemia: from highly fatal to highly curable. Blood 2008; 111: 2505-2515.
107. Quintas-Cardama A, Kantarjian H, Cortes J, Verstovsek S. Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond. Nat Rev Drug Discov 2011; 10: 127-140.
108. Verstovsek S, Kantarjian H, Mesa RA, Pardanani AD, Cortes-Franco J, Thomas DA et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 2010; 363: 1117-1127.
109. Verstovsek S, Passamonti F, Rambaldi A, Barosi G, Rosen P, Levy R et al. A phase 2 study of INCB018424, an oral, selective JAK1/JAK2 inhibitor, in patients with advanced polycythemia vera (PV) and essential thrombocythemia (ET) refractory to hydroxyurea. ASH Annu Meet Abstr 20 November 2009; 114. Abstract no. 311.
110. Moliterno AR, Hexner E, Roboz GJ, Carroll M, Luger S, Mascarenhas J et al. An open-label study of CEP-701 in patients with JAK2 V617F-positive PV and ET: update of 39 enrolled patients. ASH Annu Meet Abstr 20 November 2009; 114. Abstract no. 753.
111. Paquette R, Sokol L, Shah NP, Silver RT, List AF, Clary DO et al. A phase I study of XL019, a selective JAK2 inhibitor, in patients with polycythemia vera. ASH Annu Meet Abstr 16 November 2008; 112. Abstract no. 2810.
112. Carrier M, Le Gal G, Tay J, Wu C, Lee AY. Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta-analysis. J Thromb Haemost 2011; 9: 653-663.
113. Esteller M. Epigenetics in cancer. N Engl J Med 2008; 358: 1148-1159.
114. Guerini V, Barbui V, Spinelli O, Salvi A, Dellacasa C, Carobbio A et al. The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2(V617F). Leukemia 2008; 22: 740-747. (Pubitemid 351552623)
115. Rambaldi A, Dellacasa CM, Finazzi G, Carobbio A, Ferrari ML, Guglielmelli P et al. A pilot study of the histone-deacetylase inhibitor givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms. Br J Haematol 2010; 150: 446-455.
116. Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, Gallus AS et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363: 2499-2510.
117. Connolly SJ, Eikelboom J, Joyner C, Diener HC, Hart R, Golitsyn S et al. Apixaban in patients with atrial fibrillation. N Engl J Med 2011; 364: 806-817.
118. Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009; 361: 2342-2352.
119. James AH. Pregnancy-associated thrombosis. Hematology Am Soc Hematol Educ Program 2009, 277-285.
120. Robinson S, Bewley S, Hunt BJ, Radia DH, Harrison CN. The management and outcome of 18 pregnancies in women with polycythemia vera. Haematologica 2005; 90: 1477-1483. (Pubitemid 41658760)
121. Passamonti F, Randi ML, Rumi E, Pungolino E, Elena C, Pietra D et al. Increased risk of pregnancy complications in patients with essential thrombocythemia carrying the JAK2 (617V > F) mutation. Blood 2007; 110: 485-489. (Pubitemid 47105385)
122. Niemi T, Armstrong E. Thromboprophylactic management in the neurosurgical patient with high risk for both thrombosis and intracranial bleeding. Curr Opin Anaesthesiol 2010; 23: 558-563.
123. Deitelzweig SB, McKean SC, Amin AN, Brotman DJ, Jaffer AK, Spyropoulos AC. Prevention of venous thromboembolism in the orthopedic surgery patient. Cleve Clin J Med 2008; 75 (Suppl 3): S27-S36.
124. Ruggeri M, Rodeghiero F, Tosetto A, Castaman G, Scognamiglio F, Finazzi G et al. Postsurgery outcomes in patients with polycythemia vera and essential thrombocythemia: a retrospective survey. Blood 2008; 111: 666-671.
125. Mesa RA, Nagorney DS, Schwager S, Allred J, Tefferi A. Palliative goals, patient selection, and perioperative platelet management: outcomes and lessons from 3 decades of splenectomy for myelofibrosis with myeloid metaplasia at the Mayo Clinic. Cancer 2006; 107: 361-370. (Pubitemid 44036566)
126. Cadili A, de Gara C. Complications of splenectomy. Am J Med 2008; 121: 371-375. (Pubitemid 351626015)
127. Koster T, Rosendaal FR, Briet E, van der Meer FJ, Colly LP, Trienekens PH et al. Protein C deficiency in a controlled series of unselected outpatients: an infrequent but clear risk factor for venous thrombosis (Leiden Thrombophilia Study). Blood 1995; 85: 2756-2761.